Citigroup's decision to maintain a Neutral rating on Cardinal Health indicates that the analyst does not see significant upside or downside potential in the short term. However, the raised price target from $88 to $90 suggests a slightly more positive outlook on the stock. The impact on the stock price is expected to be neutral in the short term.